TNFRSF8 and neoplasm: The in vivo anticancer efficacy of this group of ADC have been proven in numerous xenograft models of acute myeloid leukemia, non-Hodgkin’s lymphoma (Burkittlymphoma and follicular lymphoma, CD19 as antigen, 60%–100% of mice with tumor regression), and Hodgkin’s lymphoma (CD30 as antigen, 80% of mice with tumor regression when administered at 10 mg/kg) (Neumann et al., 2018).